Finance1 min read

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

By · Via MarketWatch Top Stories · Published by Everything Blog

In short

Shares of Summit Therapeutics declined following guidance from the U.S. Food and Drug Administration regarding its lung-cancer drug. The agency recommended that the biotechnology company conduct a new clinical trial for the treatment. This downward movement intensified after a regulatory disclosure provided far more extensive details than what Summit Therapeutics had shared the prior Sunday.

Key points

  • Federal health regulators have recommended an additional clinical study for the lung-canc…: Federal health regulators have recommended an additional clinical study for the lung-cancer treatment.
  • Investor confidence weakened as official regulatory statements provided more details than…: Investor confidence weakened as official regulatory statements provided more details than the company disclosed.
  • The biotechnology firm faces renewed pressure on its equity valuation following the agenc…: The biotechnology firm faces renewed pressure on its equity valuation following the agency's trial guidance.

Sources checked by our analysis pipeline: 1

The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.

Finance